Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
作者信息
Sacchi Stefano, Marcheselli Raffaella, Bari Alessia, Buda Gabriele, Molinari Anna Lia, Baldini Luca, Vallisa Daniele, Cesaretti Marina, Musto Pellegrino, Ronconi Sonia, Specchia Giorgina, Silvestris Franco, Guardigni Luciano, Ferrari Angela, Chiapella Annalisa, Carella Angelo Michele, Santoro Armando, Di Raimondo Francesco, Marcheselli Luigi, Pozzi Samantha
机构信息
Department of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini
Department of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Rimini.
出版信息
Haematologica. 2016 May;101(5):e196-9. doi: 10.3324/haematol.2015.139329. Epub 2016 Feb 8.
Abstract
摘要
相似文献
1
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.来那度胺联合利妥昔单抗治疗复发性惰性非滤泡性淋巴瘤的安全性和疗效：意大利淋巴瘤基金会进行的一项II期研究的最终结果
Haematologica. 2016 May;101(5):e196-9. doi: 10.3324/haematol.2015.139329. Epub 2016 Feb 8.
2
Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.来那度胺和利妥昔单抗治疗初治惰性非霍奇金淋巴瘤患者后皮疹的特征与管理
Haematologica. 2015 Nov;100(11):e454-7. doi: 10.3324/haematol.2015.131144. Epub 2015 Aug 6.
3
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.来那度胺和利妥昔单抗用于未经治疗的惰性淋巴瘤的安全性及活性：一项开放标签的2期试验
Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.
4
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.来那度胺、利妥昔单抗、环磷酰胺和地塞米松（LR-CD）治疗初治需要治疗的低级别非霍奇金淋巴瘤的 2 期研究。
Am J Hematol. 2017 May;92(5):467-472. doi: 10.1002/ajh.24693. Epub 2017 Mar 22.
5
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.来那度胺联合利妥昔单抗可使复发或难治性惰性非霍奇金淋巴瘤患者产生持久的临床反应。
Br J Haematol. 2014 May;165(3):375-81. doi: 10.1111/bjh.12755. Epub 2014 Mar 7.
6
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.利妥昔单抗联合来那度胺治疗晚期未经治疗的滤泡性淋巴瘤。
N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.
7
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.二线利妥昔单抗、来那度胺和苯达莫司汀治疗套细胞淋巴瘤：意大利淋巴瘤基金会的一项II期临床试验
Haematologica. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211. Epub 2017 Jan 12.
8
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.利妥昔单抗、来那度胺和伊布替尼用于既往未治疗的滤泡性淋巴瘤的1期试验：联盟A051103
Blood. 2016 Nov 24;128(21):2510-2516. doi: 10.1182/blood-2016-06-718106. Epub 2016 Oct 3.
9
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.来那度胺联合 R-CHOP21 方案治疗未经治疗的老年弥漫性大 B 细胞淋巴瘤患者：REAL07 开放标签、多中心、Ⅱ期临床试验结果。
Lancet Oncol. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3. Epub 2014 May 13.
10
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.来那度胺联合小剂量地塞米松和利妥昔单抗治疗利妥昔单抗耐药的惰性和套细胞淋巴瘤可获得持久缓解。
Cancer. 2014 Jan 15;120(2):222-8. doi: 10.1002/cncr.28405. Epub 2013 Oct 7.
引用本文的文献
1
Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.小淋巴细胞淋巴瘤在慢性淋巴细胞白血病临床试验中的代表性不足。
Eur J Haematol. 2025 Apr;114(4):636-640. doi: 10.1111/ejh.14376. Epub 2024 Dec 27.
2
Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints.具有多个终点的多臂多阶段II期随机临床试验的贝叶斯最优设计
Stat Biopharm Res. 2024;16(3):315-325. doi: 10.1080/19466315.2024.2344543. Epub 2024 May 17.
3
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.奥妥珠单抗-阿替利珠单抗-来那度胺治疗复发/难治性滤泡性淋巴瘤患者：Ib/II期试验的最终分析
Blood Cancer J. 2021 Aug 20;11(8):147. doi: 10.1038/s41408-021-00539-8.
4
Sample Size Requirements for Calibrated Approximate Credible Intervals for Proportions in Clinical Trials.临床试验中比例的校准近似可信区间的样本量要求。
Int J Environ Res Public Health. 2021 Jan 12;18(2):595. doi: 10.3390/ijerph18020595.
5
Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.早期临床试验的模型辅助设计：简单与卓越并存
JCO Precis Oncol. 2019 Oct 24;3. doi: 10.1200/PO.19.00032. eCollection 2019.
6
Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.来那度胺-利妥昔单抗联合免疫疗法通过互补的作用机制激活滤泡性淋巴瘤的抗肿瘤免疫并诱导肿瘤细胞死亡。
Br J Haematol. 2019 Apr;185(2):240-253. doi: 10.1111/bjh.15797. Epub 2019 Feb 14.
本文引用的文献
1
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).来那度胺单药与来那度胺联合利妥昔单抗治疗复发性滤泡性淋巴瘤患者的随机试验：CALGB 50401（联盟）
J Clin Oncol. 2015 Nov 1;33(31):3635-40. doi: 10.1200/JCO.2014.59.9258. Epub 2015 Aug 24.
2
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.来那度胺和利妥昔单抗用于未经治疗的惰性淋巴瘤的安全性及活性：一项开放标签的2期试验
Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.
3
Towards a chemotherapy-free approach in indolent lymphoma.惰性淋巴瘤的无化疗治疗方法探索
Lancet Oncol. 2014 Nov;15(12):1281-2. doi: 10.1016/S1470-2045(14)70488-7. Epub 2014 Oct 15.
4
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.来那度胺联合利妥昔单抗可使复发或难治性惰性非霍奇金淋巴瘤患者产生持久的临床反应。
Br J Haematol. 2014 May;165(3):375-81. doi: 10.1111/bjh.12755. Epub 2014 Mar 7.
5
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.苯达莫司汀-利妥昔单抗或 R-CHOP/R-CVP 一线治疗惰性 NHL 或 MCL 的随机试验：BRIGHT 研究。
Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327. Epub 2014 Mar 3.
6
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.来那度胺单药治疗可使复发或难治性惰性非霍奇金淋巴瘤产生持久缓解。
J Clin Oncol. 2009 Nov 10;27(32):5404-9. doi: 10.1200/JCO.2008.21.1169. Epub 2009 Oct 5.
7
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.来那度胺与利妥昔单抗对套细胞淋巴瘤的体内外协同抗肿瘤作用
Am J Hematol. 2009 Sep;84(9):553-9. doi: 10.1002/ajh.21468.
8
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.免疫调节药物可刺激自然杀伤细胞功能，改变树突状细胞的细胞因子产生，并抑制血管生成，从而增强利妥昔单抗在体内的抗肿瘤活性。
Br J Haematol. 2008 Jan;140(1):36-45. doi: 10.1111/j.1365-2141.2007.06841.x. Epub 2007 Nov 9.
9
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.在一线和挽救治疗中引入利妥昔单抗已改善了晚期滤泡性淋巴瘤患者的治疗结果。
Cancer. 2007 May 15;109(10):2077-82. doi: 10.1002/cncr.22649.
10
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.非霍奇金淋巴瘤反应标准规范化国际研讨会报告。美国国立癌症研究所赞助的国际工作组。
J Clin Oncol. 1999 Apr;17(4):1244. doi: 10.1200/JCO.1999.17.4.1244.
Zotero 插件